株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

乳癌リキッドバイオプシーの世界市場 (〜2022年):市場予測・影響因子・投資動向・競合分析

Breast Cancer Liquid Biopsy Market by Circulating Biomarkers, Region, End User, Investments, Market Dynamics, Platform Comparison (NGS, PCR), Competitive Landscape (Acquisition, Mergers, Collaboration, Competitive technology) - Global Forecasts to 2022

発行 MarketsandMarkets 商品コード 682012
出版日 ページ情報 英文 83 Pages
即納可能
価格
本日の銀行送金レート: 1USD=108.34円で換算しております。
Back to Top
乳癌リキッドバイオプシーの世界市場 (〜2022年):市場予測・影響因子・投資動向・競合分析 Breast Cancer Liquid Biopsy Market by Circulating Biomarkers, Region, End User, Investments, Market Dynamics, Platform Comparison (NGS, PCR), Competitive Landscape (Acquisition, Mergers, Collaboration, Competitive technology) - Global Forecasts to 2022
出版日: 2018年08月03日 ページ情報: 英文 83 Pages
概要

世界の乳癌リキッドバイオプシーの市場は予測期間中23.1%のCAGR (年間複合成長率) で推移し、2017年の1億4540万米ドルから、2022年には4億1110万米ドルの規模に成長すると予測されています。乳癌の有病率の拡大、非侵襲的手術が好まれる傾向、R&D資金のアベイラビリティなどの要因が同市場の成長を推進しています。

当レポートでは、世界の乳癌リキッドバイオプシーの市場を調査し、市場および技術の概要、市場成長への各種影響因子の分析、政府・民間による投資およびイニチアチブの動向、循環バイオマーカー区分・エンドユーザー・地域別の市場規模の推移と予測、競合技術、主要企業のプロファイルなどをまとめています。

第1章 リキッドバイオプシー:市場概要

  • イントロダクション
  • リキッドバイオプシーとバイオマーカー
  • マイルストーン

第2章 リキッドバイオプシー:循環バイオマーカー

  • 血中循環腫瘍DNA (ctDNA) 向けリキッドバイオプシー市場
  • ctDNAアプローチ:用途と制約
  • CTC分離手法

第3章 リキッドバイオプシー:市場概要

  • イントロダクション
    • 成長推進因子
    • 成長抑制因子

第4章 大型投資・イニチアチブ

  • 政府資金供給&イニチアチブ
  • 産業投資&イニチアチブ

第5章 乳癌リキッドバイオプシー市場

  • 世界的シナリオ
  • 乳癌診断におけるリキッドバイオプシーおよびCTCの可能性

第6章 リキッドバイオプシー市場:競合環境

  • イントロダクション
  • 主要戦略
    • M&A
    • 製品投入
    • 合意・提携・協力
  • 競合技術ポートフォリオ

第7章 付録

図表

LIST OF TABLES

  • TABLE 1: CTDNA APPROACHES: APPLICATIONS AND LIMITATIONS
  • TABLE 2: METHODS FOR CTC ISOLATION-1
  • TABLE 3: METHODS FOR CTC ISOLATION -2
  • TABLE 4: CONFERENCES & AWARENESS PROGRAMS ON LIQUID BIOPSY
  • TABLE 5: UPCOMING CONFERENCES & AWARENESS PROGRAMS ON LIQUID BIOPSY
  • TABLE 6: GOVERNMENT FUNDING & INITIATIVES - NORTH AMERICA
  • TABLE 7: GOVERNMENT FUNDING & INITIATIVES - EUROPE
  • TABLE 8: GOVERNMENT FUNDING & INITIATIVES - ASIA PACIFIC
  • TABLE 9: GOVERNMENT FUNDING & INITIATIVES - REST OF THE WORLD
  • TABLE 10: MAJOR INVESTMENTS IN THE LIQUID BIOPSY MARKET (2010-2017) -1,2,3,4,5,6
  • TABLE 11: BREAST CANCER LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2015-2022 (USD MILLION)
  • TABLE 12: BREAST CANCER LIQUID BIOPSY MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 13: BREAST CANCER LIQUID BIOPSY MARKET, BY END USER, 2015-2022 (USD MILLION)
  • TABLE 14: BREAST CANCER CTDNA MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 15: MAJOR PLAYERS AND COMPETITIVE TECHNOLOGY PORTFOLIO - 1,2,3,4,5,6,7

LIST OF FIGURES

  • FIGURE 1: ISSUES ADDRESSED BY LIQUID BIOPSY
  • FIGURE 2: LIQUID BIOPSY: DETECTION OF CANCER BIOMARKERS
  • FIGURE 3: MILESTONES IN LIQUID BIOPSY
  • FIGURE 4: LIQUID BIOPSY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 5: GLOBAL CANCER MORTALITY STATISTICS (2012)
  • FIGURE 6: BIOMARKERS USED IN CURRENT LIQUID BIOPSY TESTS
  • FIGURE 7: PUBMED PUBLICATIONS ON LIQUID BIOPSY
  • FIGURE 8: INVESTMENTS IN LIQUID BIOPSY: 2016 & 2017 (USED MILLION)
  • FIGURE 9: NGS FUND-RAISING IN 2017 (USD MILLION)
  • FIGURE 10: BREAST CANCER LIQUID BIOPSY: MARKET OVERVIEW
  • FIGURE 11: LIQUID BIOPSY MARKET BY CIRCULATING BIOMARKERS (CAGR 2017 - 2022)
目次
Product Code: MD 6502

"Global breast cancer liquid biopsy market projected to grow at a CAGR of 23.1%"

The global breast cancer liquid biopsy market is estimated to grow at a CAGR of 23.1% from 2017 to 2022, from USD 145.4 million in 2017 to reach USD 411.1 million by 2022. Increasing prevalence of breast cancer, increasing preference for noninvasive procedures, and availability of funding for liquid biopsy R&D are some of the key factors driving the growth of the market. Unclear regulatory and reimbursement scenario is one of the major challenges faced by the market.

"Cell-free DNA to register the highest CAGR during the forecast period"

Based on circulating biomarkers, the market is categorized into circulating tumor cells (CTCs), cell-free DNA (cfDNA), extracellular vesicles (EVs), and other circulating biomarkers. The cfDNA segment is the fastest-growing segment in the circulating biomarkers market during the forecast period. This is due to the growing interest in cfDNA research from biofluids such as the blood of cancer patients as a means of disease diagnosis and therapeutic monitoring.

"Reference laboratories to register the largest share during the forecast period"

Based on end user, the market is categorized into reference laboratories, hospitals and physician laboratories, and other end users. The reference laboratories segment is the largest end-user segment of the global breast cancer liquid biopsy market. Reference laboratories are well-equipped large laboratories with facilities for genomic testing of samples, thus receiving major share of samples from hospitals and private practitioners.

"Asia Pacific to witness the highest growth during the forecast period (2017-2022)"

North America is expected to account for the largest share of the global breast cancer liquid biopsy market in 2017, while Asia Pacific is expected to witness the highest growth during 2017 to 2022. Growing demand for non-invasive treatment, rising incidence of breast cancer, and improving healthcare infrastructure are driving the growth of breast cancer liquid biopsy market in this region.

Break of primary participants was as mentioned below:

  • By Company Type - Tier 1- 15%, Tier 2- 45%, and Tier 3-40%
  • By Designation - C-level- 27%, Director Level-33%, Others-40%
  • By Region - North America-25%, Europe-45%, Asia-Pacific-15%, RoW-15%

Some of the major market players in the breast cancer liquid biopsy market are: QIAGEN N.V. (Netherlands), Roche Diagnostics (US), Bio-Rad Laboratories (US), Myriad Genetics (US), Menarini Silicon Biosystems (Italy), Illumina (US), Cynvenio Biosystems, Inc. (US) Genomic Health, Inc. (US), Thermo Fisher Scientific Inc. (US), Fluxion Biosciences, Inc. (US), Biodesix, Inc. (US), Guardant Health, Inc. (US), and Isogen Life Science B.V. (Netherlands).

Research Coverage:

The report analyzes the breast cancer liquid biopsy market and aims at estimating market size and future growth potential of this market based on various segments such as by circulating biomarker, end user, and region. The report also includes competitive analysis of the key players in this market along with their company profiles, product offerings, recent developments, and key market strategies.

Reasons to Buy the Report:

The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help them, garner a greater share. Firms purchasing the report could use one or any combination of the below-mentioned five strategies.

This report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on product portfolios offered by the top players in the global liquid biopsy market. The report analyzes the global liquid biopsy market by product, medical specialty, application, end user, and region
  • Innovation: Detailed insights on upcoming trends and product launches in the global breast cancer liquid biopsy market
  • Market Development: Comprehensive information on the lucrative emerging markets by product, circulating biomarkers, end user, and region
  • Market Diversification: Exhaustive information about growing geographies, recent developments, and investments in the global breast cancer liquid biopsy market
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, products, and capabilities of liquid biopsy products of leading players in the global market

TABLE OF CONTENTS

1. LIQUID BIOPSY: MARKET AT A GLANCE

  • 1.1. INTRODUCTION
  • 1.2. ISSUES ADDRESSED BY LIQUID BIOPSY & BIOMARKERS DETECTED
  • 1.3. MILESTONES IN LIQUID BIOPSY

2. LIQUID BIOPSY: CIRCULATING BIOMARKERS

  • 2.1. LIQUID BIOPSY MARKET FOR CIRCULATING TUMOR DNA (CTDNA)
  • 2.2. CTDNA APPROACHES: APPLICATIONS AND LIMITATIONS
  • 2.3. METHODS FOR CTC ISOLATION

3. LIQUID BIOPSY: MARKET OVERVIEW

  • 3.1. INTRODUCTION
    • 3.1.1. DRIVERS
      • 3.1.2.1. HIGH BURDEN OF CANCER
      • 3.1.2.2. INCREASING PREFERENCE FOR NONINVASIVE PROCEDURES
      • 3.1.2.3. INITIATIVES UNDERTAKEN BY GOVERNMENTS AND GLOBAL HEALTH ORGANIZATIONS
      • 3.1.2.4. TECHNOLOGICAL ADVANCEMENTS
      • 3.1.2.5. RISING EMPHASIS ON PERSONALIZED MEDICINE
      • 3.1.2.6. AVAILABILITY OF FUNDING FOR LIQUID BIOPSY R&D
    • 3.1.2. RESTRAINTS
      • 3.1.2.1. LOW SENSITIVITY AND SPECIFICITY
    • 3.1.3. OPPORTUNITIES
      • 3.1.3.1. GROWING INTEREST IN LIQUID BIOPSY
    • 3.1.4. CHALLENGES
      • 3.1.4.1. UNCLEAR REGULATORY AND REIMBURSEMENT SCENARIO

4. MAJOR INVESTMENTS & INITIATIVES

  • 4.1. GOVERNMENT FUNDING & INITIATIVES
  • 4.2. INDUSTRY INVESTMENTS AND INITIATIVES

5. BREAST CANCER LIQUID BIOPSY MARKET

  • 5.1. BREAST CANCER LIQUID BIOPSY MARKET: GLOBAL SCENARIO
  • 5.2. POTENTIAL OF LIQUID BIOPSY AND CTC IN BREAST CANCER DIAGNOSIS

6. LIQUID BIOPSY MARKET: COMPETITIVE LANDSCAPE

  • 6.1. INTRODUCTION
  • 6.2. KEY STRATEGIES
    • 6.2.1. ACQUISITIONS AND MERGERS
    • 6.2.2. PRODUCT LAUNCHES
    • 6.2.3. AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS
  • 6.3. LIQUID BIOPSY MARKET: COMPETITIVE TECHNOLOGY PORTFOLIO

7. APPENDIX

  • 7.1. KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 7.2. INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
  • 7.3. AVAILABLE CUSTOMIZATIONS
  • 7.4. RELATED REPORTS
  • 7.5. AUTHOR DETAILS
Back to Top